JP2007518682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007518682A5 JP2007518682A5 JP2006519250A JP2006519250A JP2007518682A5 JP 2007518682 A5 JP2007518682 A5 JP 2007518682A5 JP 2006519250 A JP2006519250 A JP 2006519250A JP 2006519250 A JP2006519250 A JP 2006519250A JP 2007518682 A5 JP2007518682 A5 JP 2007518682A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- substituted
- unsaturated heterocyclic
- optionally substituted
- heterocyclic ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 150000001555 benzenes Chemical group 0.000 claims 3
- VVAFXPPGIPMLKM-UJWQCDCRSA-N Nc1ccc(Cc2ccc(N[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(Cl)c2)cc1Cl Chemical compound Nc1ccc(Cc2ccc(N[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(Cl)c2)cc1Cl VVAFXPPGIPMLKM-UJWQCDCRSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (1)
- 式Ｉ
（式中、環Ａおよび環Ｂは、（１）環Ａが置換されていてもよい単環不飽和異項環であり、環Ｂが置換されていてもよい単環不飽和異項環、置換されていてもよい二環縮合不飽和異項環、または置換されていてもよいベンゼン環であるか、（２）環Ａが置換されていてもよいベンゼン環であり、環Ｂが置換されていてもよい単環不飽和異項環、置換されていてもよい二環縮合不飽和異項環、または置換されていてもよいベンゼン環であるか、または（３）環Ａが置換されていてもよい二環縮合不飽和異項環であり、ここにおいて−ＮＲ−基および−ＣＨ２−基は両方とも、当該二環縮合不飽和異項環の同じ環に結合し、環Ｂが置換されていてもよい単環不飽和異項環、置換されていてもよい二環縮合不飽和異項環、または置換されていてもよいベンゼン環であり、
Ｒは水素原子、低級アルキル基、低級アルカノイル基または低級アルコキシカルボニル基である）
で示される化合物、その医薬的に許容しうる塩、またはそれらのプロドラッグ；
ただし、Ｎ−［４−［（４−アミノ−３−クロロフェニル）メチル］−２−クロロフェニル］−β−Ｄ−グルコピラノシルアミンを除く。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49152303P | 2003-08-01 | 2003-08-01 | |
| US60/491,523 | 2003-08-01 | ||
| PCT/JP2004/011311 WO2005012321A1 (en) | 2003-08-01 | 2004-07-30 | Novel compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007518682A JP2007518682A (ja) | 2007-07-12 |
| JP2007518682A5 true JP2007518682A5 (ja) | 2007-09-20 |
| JP4717811B2 JP4717811B2 (ja) | 2011-07-06 |
Family
ID=34115512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006519250A Expired - Fee Related JP4717811B2 (ja) | 2003-08-01 | 2004-07-30 | 新規化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7521430B2 (ja) |
| EP (1) | EP1654269B1 (ja) |
| JP (1) | JP4717811B2 (ja) |
| KR (1) | KR101101500B1 (ja) |
| CN (2) | CN1829728A (ja) |
| AU (1) | AU2004260760B2 (ja) |
| BR (1) | BRPI0413233A (ja) |
| CA (1) | CA2534022C (ja) |
| EA (1) | EA011025B1 (ja) |
| ES (1) | ES2527053T3 (ja) |
| IL (1) | IL173051A (ja) |
| MX (1) | MXPA06001273A (ja) |
| NO (1) | NO333679B1 (ja) |
| NZ (1) | NZ545305A (ja) |
| TW (1) | TWI377209B (ja) |
| UA (5) | UA86042C2 (ja) |
| WO (1) | WO2005012321A1 (ja) |
| ZA (2) | ZA200601686B (ja) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| ME00411B (me) * | 2003-08-01 | 2011-10-10 | Tanabe Seiyaku Co | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| TWI365186B (en) | 2005-01-31 | 2012-06-01 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| JP5073948B2 (ja) * | 2005-01-31 | 2012-11-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| TWI418556B (zh) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| UY30730A1 (es) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| JP5298025B2 (ja) * | 2006-12-04 | 2013-09-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体 |
| US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| RS56990B1 (sr) | 2007-09-10 | 2018-05-31 | Janssen Pharmaceutica Nv | Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| CA2725047A1 (en) | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
| EA018492B1 (ru) | 2008-08-28 | 2013-08-30 | Пфайзер Инк. | Диоксабицикло[3.2.1]октан-2,3,4-триольные производные |
| US20110230403A1 (en) * | 2008-09-19 | 2011-09-22 | Novartis Ag | Glycoside derivatives and uses thereof |
| US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| PL2451797T3 (pl) | 2009-07-10 | 2013-08-30 | Janssen Pharmaceutica Nv | Proces krystalizacji dla 1-(ß-D-glukopiranozylo)-4-metylo-3-[5-(4-fluorofenylo)-2-tienylometylo]benzenu |
| WO2011047113A1 (en) * | 2009-10-14 | 2011-04-21 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
| GEP20146104B (en) | 2009-11-02 | 2014-05-27 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| BR112012028857B1 (pt) | 2010-05-11 | 2021-02-09 | Janssen Pharmaceutica Nv | Composições farmacêuticas administráveis por via oral que compreendem derivados de 1- (beta-d glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt |
| CN103596944B (zh) | 2011-04-13 | 2017-02-22 | 詹森药业有限公司 | 可用作sglt2的抑制剂的化合物的制备方法 |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| US20160002276A1 (en) * | 2013-02-26 | 2016-01-07 | Mitsubishi Tanabe Pharma Corporation | METHOD FOR PRODUCING a-HALO-TETRAACYL-GLUCOSE |
| CN103896930B (zh) * | 2014-04-02 | 2016-08-17 | 安徽联创生物医药股份有限公司 | 卡格列净半水合物药用晶型的制备方法 |
| ES2711804T3 (es) | 2014-05-27 | 2019-05-07 | Glenmark Pharmaceuticals Ltd | Proceso para preparación de canagliflozina |
| CN104045673B (zh) * | 2014-06-06 | 2017-01-18 | 安徽省食品药品检验研究院 | 双‑三氮唑缀合的假二糖衍生物及其制备方法 |
| CN104478968A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| CN106188022A (zh) * | 2015-04-30 | 2016-12-07 | 上海医药工业研究院 | 伊格列净的制备方法 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| EA202190226A1 (ru) | 2018-07-19 | 2021-06-16 | Астразенека Аб | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ |
| WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| EP4315350A1 (en) | 2021-04-01 | 2024-02-07 | AstraZeneca UK Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
| WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1075626B (de) * | 1960-02-18 | Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M | Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden | |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| ES2254376T3 (es) * | 2000-03-17 | 2006-06-16 | Kissei Pharmaceutical Co., Ltd. | Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados. |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| CN1293087C (zh) * | 2000-09-29 | 2007-01-03 | 橘生药品工业株式会社 | 吡喃葡糖氧基苄基苯衍生物及其药物组合物 |
| CA2429833A1 (en) * | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| SK287786B6 (sk) | 2000-12-28 | 2011-09-05 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie |
| TWI255817B (en) * | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| EP1432720A1 (en) * | 2001-09-05 | 2004-06-30 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2004
- 2004-07-29 UA UAA200605348A patent/UA86042C2/ru unknown
- 2004-07-30 UA UAA200605346A patent/UA87991C2/ru unknown
- 2004-07-30 EP EP04771313.6A patent/EP1654269B1/en not_active Not-in-force
- 2004-07-30 WO PCT/JP2004/011311 patent/WO2005012321A1/en active Application Filing
- 2004-07-30 UA UAA200602256A patent/UA83377C2/uk unknown
- 2004-07-30 BR BRPI0413233-5A patent/BRPI0413233A/pt not_active IP Right Cessation
- 2004-07-30 EA EA200600348A patent/EA011025B1/ru not_active IP Right Cessation
- 2004-07-30 UA UAA200605347A patent/UA85569C2/ru unknown
- 2004-07-30 UA UAA200605349A patent/UA86599C2/ru unknown
- 2004-07-30 ES ES04771313.6T patent/ES2527053T3/es active Active
- 2004-07-30 US US10/566,585 patent/US7521430B2/en not_active Expired - Fee Related
- 2004-07-30 TW TW093122844A patent/TWI377209B/zh not_active IP Right Cessation
- 2004-07-30 AU AU2004260760A patent/AU2004260760B2/en not_active Ceased
- 2004-07-30 KR KR1020067002158A patent/KR101101500B1/ko not_active IP Right Cessation
- 2004-07-30 NZ NZ545305A patent/NZ545305A/en not_active IP Right Cessation
- 2004-07-30 JP JP2006519250A patent/JP4717811B2/ja not_active Expired - Fee Related
- 2004-07-30 MX MXPA06001273A patent/MXPA06001273A/es active IP Right Grant
- 2004-07-30 CN CNA2004800220063A patent/CN1829728A/zh active Pending
- 2004-07-30 CN CN2010105463425A patent/CN102060888A/zh active Pending
- 2004-07-30 CA CA2534022A patent/CA2534022C/en not_active Expired - Fee Related
-
2006
- 2006-01-10 IL IL173051A patent/IL173051A/en not_active IP Right Cessation
- 2006-01-16 NO NO20060219A patent/NO333679B1/no not_active IP Right Cessation
- 2006-02-27 ZA ZA200601686A patent/ZA200601686B/en unknown
- 2006-05-15 ZA ZA200603880A patent/ZA200603880B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007518682A5 (ja) | ||
| JP2008505194A5 (ja) | ||
| JP2007510619A5 (ja) | ||
| JP2007508362A5 (ja) | ||
| JP2005053931A5 (ja) | ||
| JP2007508359A5 (ja) | ||
| WO2007001975A8 (en) | Piperidine derivatives useful as histamine h3 antagonists | |
| JP2006526031A5 (ja) | ||
| JP2002543183A5 (ja) | ||
| JP2007523941A5 (ja) | ||
| JP2005507872A5 (ja) | ||
| JP2007500753A5 (ja) | ||
| JP2008546770A5 (ja) | ||
| JP2012510502A5 (ja) | ||
| JP2007523139A5 (ja) | ||
| JP2008514655A5 (ja) | ||
| EA200600348A1 (ru) | Новые соединения | |
| JP2006522035A5 (ja) | ||
| JP2007530525A5 (ja) | ||
| JP2005503385A5 (ja) | ||
| JP2008500997A5 (ja) | ||
| JP2008510828A5 (ja) | ||
| JP2007517826A5 (ja) | ||
| JP2009520791A5 (ja) | ||
| JP2009501704A5 (ja) |